AU2003275997B8 - Novel bicyclic inhibitors of hormone sensitive lipase - Google Patents
Novel bicyclic inhibitors of hormone sensitive lipase Download PDFInfo
- Publication number
- AU2003275997B8 AU2003275997B8 AU2003275997A AU2003275997A AU2003275997B8 AU 2003275997 B8 AU2003275997 B8 AU 2003275997B8 AU 2003275997 A AU2003275997 A AU 2003275997A AU 2003275997 A AU2003275997 A AU 2003275997A AU 2003275997 B8 AU2003275997 B8 AU 2003275997B8
- Authority
- AU
- Australia
- Prior art keywords
- represent
- formula
- benzotriazole
- och
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000000019 Sterol Esterase Human genes 0.000 title claims description 8
- 108010055297 Sterol Esterase Proteins 0.000 title claims description 8
- 239000003112 inhibitor Substances 0.000 title description 9
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 78
- -1 phenoxy, benzoyl Chemical group 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 25
- 229910052794 bromium Inorganic materials 0.000 claims description 24
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 23
- 239000012964 benzotriazole Substances 0.000 claims description 23
- 229910004013 NO 2 Inorganic materials 0.000 claims description 22
- 229910052801 chlorine Inorganic materials 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 102100026020 Hormone-sensitive lipase Human genes 0.000 claims description 17
- 150000001565 benzotriazoles Chemical class 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 150000003254 radicals Chemical class 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 7
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- FKTIXGCTNSWZRY-UHFFFAOYSA-N 2h-benzotriazole-4-carbonyl chloride Chemical class ClC(=O)C1=CC=CC2=C1N=NN2 FKTIXGCTNSWZRY-UHFFFAOYSA-N 0.000 claims description 3
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 claims description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 20
- 239000000460 chlorine Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 239000000556 agonist Substances 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 230000008033 biological extinction Effects 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 229940100389 Sulfonylurea Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000016267 Leptin Human genes 0.000 description 4
- 108010092277 Leptin Proteins 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
- 229940039781 leptin Drugs 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 229950000964 pepstatin Drugs 0.000 description 4
- 108010091212 pepstatin Proteins 0.000 description 4
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 108010087765 Antipain Proteins 0.000 description 3
- 240000008886 Ceratonia siliqua Species 0.000 description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 101100421709 Schistosoma mansoni SM21.7 gene Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000002512 Orexin Human genes 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 102000005630 Urocortins Human genes 0.000 description 2
- 108010059705 Urocortins Proteins 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- AHZRGSIAWPDNOS-UHFFFAOYSA-N benzotriazole-1-carbonyl chloride Chemical compound C1=CC=C2N(C(=O)Cl)N=NC2=C1 AHZRGSIAWPDNOS-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940060975 lantus Drugs 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- LYAUICDWKQJAGX-UHFFFAOYSA-N n-(7-hydroxy-2,2,4,6-tetramethyl-1,3-dihydroinden-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamide Chemical compound COC1=CC=CC(N2CCN(CC(=O)NC3C(CC4=C3C(=C(C)C=C4C)O)(C)C)CC2)=C1 LYAUICDWKQJAGX-UHFFFAOYSA-N 0.000 description 2
- 108060005714 orexin Proteins 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 239000000777 urocortin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- ZBOYJODMIAUJHH-SANMLTNESA-N (2s)-1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound C=1C(OC)=C(CN2[C@@H](CCCC2)C(O)=O)C(OC)=CC=1OCC(C=1C)=CC=CC=1C1=CC=CC=C1 ZBOYJODMIAUJHH-SANMLTNESA-N 0.000 description 1
- AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- DFXZULCWKXJBFG-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(5-phenoxybenzotriazol-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC=C(OC=3C=CC=CC=3)C=C2N=N1 DFXZULCWKXJBFG-UHFFFAOYSA-N 0.000 description 1
- WWNDHFMHSVYGBK-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-(6-nitrobenzotriazol-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC([N+]([O-])=O)=CC=C2N=N1 WWNDHFMHSVYGBK-UHFFFAOYSA-N 0.000 description 1
- YYCXCGPSXWPIDJ-UHFFFAOYSA-N (4-methylpiperidin-1-yl)-[5-(trifluoromethyl)benzotriazol-1-yl]methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC=C(C(F)(F)F)C=C2N=N1 YYCXCGPSXWPIDJ-UHFFFAOYSA-N 0.000 description 1
- NLSPJHUNHYRNPX-UHFFFAOYSA-N (5-bromobenzotriazol-1-yl)-(3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)N1C2=CC=C(Br)C=C2N=N1 NLSPJHUNHYRNPX-UHFFFAOYSA-N 0.000 description 1
- VCMAOXNLCKZWCH-UHFFFAOYSA-N (5-bromobenzotriazol-1-yl)-(3,6-dihydro-2h-pyridin-1-yl)methanone Chemical compound N1=NC2=CC(Br)=CC=C2N1C(=O)N1CCC=CC1 VCMAOXNLCKZWCH-UHFFFAOYSA-N 0.000 description 1
- WHQCRSWUEJXXNI-UHFFFAOYSA-N (5-bromobenzotriazol-1-yl)-(3-methylpiperidin-1-yl)methanone Chemical compound C1C(C)CCCN1C(=O)N1C2=CC=C(Br)C=C2N=N1 WHQCRSWUEJXXNI-UHFFFAOYSA-N 0.000 description 1
- GQJDQVSQVPAFKG-UHFFFAOYSA-N (5-chlorobenzotriazol-1-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC=C(Cl)C=C2N=N1 GQJDQVSQVPAFKG-UHFFFAOYSA-N 0.000 description 1
- VFRLPIZYDIKSPB-UHFFFAOYSA-N (5-cyclohexylsulfanylbenzotriazol-1-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC=C(SC3CCCCC3)C=C2N=N1 VFRLPIZYDIKSPB-UHFFFAOYSA-N 0.000 description 1
- DVLGALBZJQOKBG-UHFFFAOYSA-N (5-methoxybenzotriazol-1-yl)-(3-methylpiperidin-1-yl)methanone Chemical compound N1=NC2=CC(OC)=CC=C2N1C(=O)N1CCCC(C)C1 DVLGALBZJQOKBG-UHFFFAOYSA-N 0.000 description 1
- JNIKMJPXCOXJRZ-UHFFFAOYSA-N (5-methoxybenzotriazol-1-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound N1=NC2=CC(OC)=CC=C2N1C(=O)N1CCC(C)CC1 JNIKMJPXCOXJRZ-UHFFFAOYSA-N 0.000 description 1
- YZFQZGAUZJTPFN-UHFFFAOYSA-N (5-phenoxybenzotriazol-1-yl)-[4-(trifluoromethyl)piperidin-1-yl]methanone Chemical compound C1CC(C(F)(F)F)CCN1C(=O)N1C2=CC=C(OC=3C=CC=CC=3)C=C2N=N1 YZFQZGAUZJTPFN-UHFFFAOYSA-N 0.000 description 1
- JFGDGUITICIFGC-UHFFFAOYSA-N (6-aminobenzotriazol-1-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC(N)=CC=C2N=N1 JFGDGUITICIFGC-UHFFFAOYSA-N 0.000 description 1
- RSWVFAVIVDRTFB-UHFFFAOYSA-N (6-bromobenzotriazol-1-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC(Br)=CC=C2N=N1 RSWVFAVIVDRTFB-UHFFFAOYSA-N 0.000 description 1
- AEFKHYBQHZAPJZ-UHFFFAOYSA-N (6-chloro-5-fluorobenzotriazol-1-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC(Cl)=C(F)C=C2N=N1 AEFKHYBQHZAPJZ-UHFFFAOYSA-N 0.000 description 1
- DLASOYBNZZXUCB-UHFFFAOYSA-N (6-chlorobenzotriazol-1-yl)-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC(Cl)=CC=C2N=N1 DLASOYBNZZXUCB-UHFFFAOYSA-N 0.000 description 1
- SBKJAXPHYUXFCU-UHFFFAOYSA-N (6-methylbenzotriazol-1-yl)-pyrrolidin-1-ylmethanone Chemical compound C12=CC(C)=CC=C2N=NN1C(=O)N1CCCC1 SBKJAXPHYUXFCU-UHFFFAOYSA-N 0.000 description 1
- SSSBJUJSIXZMLJ-UHFFFAOYSA-N (7-amino-3,4-dihydro-1h-isoquinolin-2-yl)-(benzotriazol-1-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1CCC2=CC=C(N)C=C2C1 SSSBJUJSIXZMLJ-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UGBPWTYVCFZMLS-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl(benzotriazol-1-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1CC2CCCCC2C1 UGBPWTYVCFZMLS-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AKMNUCBQGHFICM-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea Chemical compound C1=CN=C2C(NC(=O)NC3=CC=C4N=C(OC4=C3)C)=CC=NC2=C1 AKMNUCBQGHFICM-UHFFFAOYSA-N 0.000 description 1
- CPTUCWPSPPWPID-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinoline-2-carbonyl)benzotriazole-5-carbonitrile Chemical compound N1=NC2=CC(C#N)=CC=C2N1C(=O)N1CC2=CC=CC=C2CC1 CPTUCWPSPPWPID-UHFFFAOYSA-N 0.000 description 1
- SFJWTYFHGUHDKN-UHFFFAOYSA-N 1-(3,4-dihydro-2h-quinoline-1-carbonyl)benzotriazole-5-carbonitrile Chemical compound N1=NC2=CC(C#N)=CC=C2N1C(=O)N1C2=CC=CC=C2CCC1 SFJWTYFHGUHDKN-UHFFFAOYSA-N 0.000 description 1
- OMXRTIUYSHDUTH-UHFFFAOYSA-N 1-(3-ethyl-1-benzofuran-7-yl)piperazine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC=C2C(CC)=COC2=C1N1CCNCC1 OMXRTIUYSHDUTH-UHFFFAOYSA-N 0.000 description 1
- PMGZJNCIQHGNLT-UHFFFAOYSA-N 1-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-4-(3-phenoxyphenyl)butane-1-sulfonic acid Chemical compound CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)C(S(O)(=O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 PMGZJNCIQHGNLT-UHFFFAOYSA-N 0.000 description 1
- GUSVHVVOABZHAH-OPZWKQDFSA-N 1aw8p77hkj Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GUSVHVVOABZHAH-OPZWKQDFSA-N 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- HQSRVYUCBOCBLY-XOOFNSLWSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2s,4r)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CSC=4N(C=NN=4)C)(OC3)C=3C=CC(Cl)=CC=3)=CC=2)C=C1 HQSRVYUCBOCBLY-XOOFNSLWSA-N 0.000 description 1
- NFDFTMICKVDYLQ-UHFFFAOYSA-N 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid Chemical compound C1=C(Cl)C(OC)=CC(C2=C(SC(NC(=O)C=3N(C4=C(C)C=C(C)C=C4C=3)CC(O)=O)=N2)CCC2CCCCC2)=C1OC NFDFTMICKVDYLQ-UHFFFAOYSA-N 0.000 description 1
- YCOXJFAUNLRWPU-UHFFFAOYSA-N 2-methyl-n,n-dipropyl-9-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indol-4-amine Chemical compound C12=CC=CC=C2C=2C(N(CCC)CCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C YCOXJFAUNLRWPU-UHFFFAOYSA-N 0.000 description 1
- MNEPQKQVONSGQD-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-yl-(5-methoxybenzotriazol-1-yl)methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)N1C2=CC=C(OC)C=C2N=N1 MNEPQKQVONSGQD-UHFFFAOYSA-N 0.000 description 1
- QMDCZTCMVTZMNE-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-yl-(5-nitrobenzotriazol-1-yl)methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)N1C2=CC=C([N+](=O)[O-])C=C2N=N1 QMDCZTCMVTZMNE-UHFFFAOYSA-N 0.000 description 1
- CHFIEWICSYYKKR-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-yl-(6-nitrobenzotriazol-1-yl)methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)N1N=NC2=CC=C([N+](=O)[O-])C=C21 CHFIEWICSYYKKR-UHFFFAOYSA-N 0.000 description 1
- MKCPNTNOONNMNY-UHFFFAOYSA-N 3,6-dihydro-2h-pyridin-1-yl-(5-nitrobenzotriazol-1-yl)methanone Chemical compound N1=NC2=CC([N+](=O)[O-])=CC=C2N1C(=O)N1CCC=CC1 MKCPNTNOONNMNY-UHFFFAOYSA-N 0.000 description 1
- VVQQGCUCLGWFSK-UHFFFAOYSA-N 3-(4-methylpiperidine-1-carbonyl)benzotriazole-5-carbonitrile Chemical compound C1CC(C)CCN1C(=O)N1C2=CC(C#N)=CC=C2N=N1 VVQQGCUCLGWFSK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- TWJQZBXURHWBPV-UHFFFAOYSA-N 3-cyclohexyl-1-(4,4-dimethyl-6,7-dihydro-1h-imidazo[4,5-c]pyridin-5-yl)propan-1-one;oxalic acid Chemical compound OC(=O)C(O)=O.C1CC=2NC=NC=2C(C)(C)N1C(=O)CCC1CCCCC1 TWJQZBXURHWBPV-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- BVKYOYMIJNTOFF-UHFFFAOYSA-N CC1=CC=CC=2N(N=NC21)C(=O)N2CCC=CC2 Chemical compound CC1=CC=CC=2N(N=NC21)C(=O)N2CCC=CC2 BVKYOYMIJNTOFF-UHFFFAOYSA-N 0.000 description 1
- 101150036984 CCN3 gene Proteins 0.000 description 1
- 101100437861 Caenorhabditis elegans brc-1 gene Proteins 0.000 description 1
- 101100124528 Caenorhabditis elegans hmr-1 gene Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- DMMMNSALKMVOIA-UHFFFAOYSA-N Cl.C1=CN=C2C(NC(=O)N)=CC=NC2=C1 Chemical compound Cl.C1=CN=C2C(NC(=O)N)=CC=NC2=C1 DMMMNSALKMVOIA-UHFFFAOYSA-N 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100021587 Embryonic testis differentiation protein homolog A Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102000019432 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000898120 Homo sapiens Embryonic testis differentiation protein homolog A Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 229940122014 Lyase inhibitor Drugs 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940124757 MC-4 agonist Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical group N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UULIGRNKXHCLQN-UHFFFAOYSA-N N-[[4-[[(4-amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 UULIGRNKXHCLQN-UHFFFAOYSA-N 0.000 description 1
- 102000047330 Nephroblastoma Overexpressed Human genes 0.000 description 1
- 108700024729 Nephroblastoma Overexpressed Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- KDSZWTOCSBHVSG-UHFFFAOYSA-N [1-(4-methylpiperidine-1-carbonyl)benzotriazol-5-yl]-phenylmethanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC=C(C(=O)C=3C=CC=CC=3)C=C2N=N1 KDSZWTOCSBHVSG-UHFFFAOYSA-N 0.000 description 1
- HQNFAOXWDSYDDC-UHFFFAOYSA-N [3-(4-methylpiperidine-1-carbonyl)benzotriazol-5-yl]-phenylmethanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC(C(=O)C=3C=CC=CC=3)=CC=C2N=N1 HQNFAOXWDSYDDC-UHFFFAOYSA-N 0.000 description 1
- MEOVDAKWUFKNAY-UHFFFAOYSA-N [4-chloro-6-(trifluoromethyl)benzotriazol-1-yl]-(3,6-dihydro-2h-pyridin-1-yl)methanone Chemical compound C12=CC(C(F)(F)F)=CC(Cl)=C2N=NN1C(=O)N1CCC=CC1 MEOVDAKWUFKNAY-UHFFFAOYSA-N 0.000 description 1
- LWBSYNNTIWUYAQ-UHFFFAOYSA-N [5-[hydroxy(phenyl)methyl]benzotriazol-1-yl]-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC=C(C(O)C=3C=CC=CC=3)C=C2N=N1 LWBSYNNTIWUYAQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229950010046 avasimibe Drugs 0.000 description 1
- ASEMSXKIHXLKMQ-UHFFFAOYSA-N azepan-1-yl(benzotriazol-1-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1CCCCCC1 ASEMSXKIHXLKMQ-UHFFFAOYSA-N 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- TWLXSXDLEOKPJS-UHFFFAOYSA-N benzotriazol-1-yl(1,2,3,4-tetrahydroisoquinolin-1-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)C1C2=CC=CC=C2CCN1 TWLXSXDLEOKPJS-UHFFFAOYSA-N 0.000 description 1
- QDIFPNQOECHNHD-UHFFFAOYSA-N benzotriazol-1-yl(1,2,6-triazaspiro[2.5]oct-1-en-6-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N(CC1)CCC21N=N2 QDIFPNQOECHNHD-UHFFFAOYSA-N 0.000 description 1
- ZJEWIMWWYXQXCA-UHFFFAOYSA-N benzotriazol-1-yl(1,3-dihydroisoindol-2-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1CC2=CC=CC=C2C1 ZJEWIMWWYXQXCA-UHFFFAOYSA-N 0.000 description 1
- TVZKJTFHLUZVCN-UHFFFAOYSA-N benzotriazol-1-yl(3,4-dihydro-2h-quinolin-1-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1C2=CC=CC=C2CCC1 TVZKJTFHLUZVCN-UHFFFAOYSA-N 0.000 description 1
- XVCUTEWFIHEDBR-UHFFFAOYSA-N benzotriazol-1-yl(3,6-dihydro-2h-pyridin-1-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1CCC=CC1 XVCUTEWFIHEDBR-UHFFFAOYSA-N 0.000 description 1
- BUFMEDDIMLMLGB-UHFFFAOYSA-N benzotriazol-1-yl-(3,4-dimethylpiperidin-1-yl)methanone Chemical compound C1C(C)C(C)CCN1C(=O)N1C2=CC=CC=C2N=N1 BUFMEDDIMLMLGB-UHFFFAOYSA-N 0.000 description 1
- JTMBIMVCUQSHOS-UHFFFAOYSA-N benzotriazol-1-yl-(3-methylpiperidin-1-yl)methanone Chemical compound C1C(C)CCCN1C(=O)N1C2=CC=CC=C2N=N1 JTMBIMVCUQSHOS-UHFFFAOYSA-N 0.000 description 1
- RKPRATVIBISBFW-UHFFFAOYSA-N benzotriazol-1-yl-(4-benzylpiperidin-1-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N(CC1)CCC1CC1=CC=CC=C1 RKPRATVIBISBFW-UHFFFAOYSA-N 0.000 description 1
- XDEPWXLAPYOKBH-UHFFFAOYSA-N benzotriazol-1-yl-(4-bromopiperidin-1-yl)methanone Chemical compound C1CC(Br)CCN1C(=O)N1C2=CC=CC=C2N=N1 XDEPWXLAPYOKBH-UHFFFAOYSA-N 0.000 description 1
- CVHZMANGMAYXPK-UHFFFAOYSA-N benzotriazol-1-yl-(4-chloropiperidin-1-yl)methanone Chemical compound C1CC(Cl)CCN1C(=O)N1C2=CC=CC=C2N=N1 CVHZMANGMAYXPK-UHFFFAOYSA-N 0.000 description 1
- ONZJKALGUIRYAL-UHFFFAOYSA-N benzotriazol-1-yl-(4-ethylpiperidin-1-yl)methanone Chemical compound C1CC(CC)CCN1C(=O)N1C2=CC=CC=C2N=N1 ONZJKALGUIRYAL-UHFFFAOYSA-N 0.000 description 1
- ZWVOWJIDJRAPAR-UHFFFAOYSA-N benzotriazol-1-yl-(4-methylpiperidin-1-yl)methanone Chemical compound C1CC(C)CCN1C(=O)N1C2=CC=CC=C2N=N1 ZWVOWJIDJRAPAR-UHFFFAOYSA-N 0.000 description 1
- ITMIZDJLIOGQEQ-UHFFFAOYSA-N benzotriazol-1-yl-(4-propan-2-ylpiperidin-1-yl)methanone Chemical compound C1CC(C(C)C)CCN1C(=O)N1C2=CC=CC=C2N=N1 ITMIZDJLIOGQEQ-UHFFFAOYSA-N 0.000 description 1
- ZXAFVZPOPQRPHT-UHFFFAOYSA-N benzotriazol-1-yl-(4-tert-butylpiperidin-1-yl)methanone Chemical compound C1CC(C(C)(C)C)CCN1C(=O)N1C2=CC=CC=C2N=N1 ZXAFVZPOPQRPHT-UHFFFAOYSA-N 0.000 description 1
- KFZDEXXNCLOSMF-UHFFFAOYSA-N benzotriazol-1-yl-(6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1CC2=CC=C(OC)C=C2CC1 KFZDEXXNCLOSMF-UHFFFAOYSA-N 0.000 description 1
- YKLLJJJXTLRUSJ-UHFFFAOYSA-N benzotriazol-1-yl-(7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1CCC2=CC=C(OC)C=C2C1 YKLLJJJXTLRUSJ-UHFFFAOYSA-N 0.000 description 1
- XBAGRZNZSLEVLM-UHFFFAOYSA-N benzotriazol-1-yl-(7-nitro-3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound N1=NC2=CC=CC=C2N1C(=O)N1CCC2=CC=C([N+](=O)[O-])C=C2C1 XBAGRZNZSLEVLM-UHFFFAOYSA-N 0.000 description 1
- MLKWBEIIWQDXCY-UHFFFAOYSA-N benzotriazol-1-yl-[4-(trifluoromethyl)piperidin-1-yl]methanone Chemical compound C1CC(C(F)(F)F)CCN1C(=O)N1C2=CC=CC=C2N=N1 MLKWBEIIWQDXCY-UHFFFAOYSA-N 0.000 description 1
- UUMXWUNNKCQWHS-UHFFFAOYSA-N benzotriazole-1-carboxamide Chemical class C1=CC=C2N(C(=O)N)N=NC2=C1 UUMXWUNNKCQWHS-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- NVWVENISXPCRDU-UHFFFAOYSA-N ethyl 1-(benzotriazole-1-carbonyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C(=O)N1C2=CC=CC=C2N=N1 NVWVENISXPCRDU-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229950005809 implitapide Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003566 lomitapide Drugs 0.000 description 1
- QKVKOFVWUHNEBX-UHFFFAOYSA-N lomitapide mesylate Chemical compound CS(O)(=O)=O.C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 QKVKOFVWUHNEBX-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QHAUNOSFCYFTQQ-UHFFFAOYSA-N methyl 3-(4-methylpiperidine-1-carbonyl)benzotriazole-5-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2N=NN1C(=O)N1CCC(C)CC1 QHAUNOSFCYFTQQ-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- LXEDKSZTPGCEPU-UHFFFAOYSA-N n-[2-(3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound O=C1N(C)N=C2CCN(C(=O)C(NC(=O)C3C(C4=CC=CC=C4CC3)N)C=3C=CC(Cl)=CC=3)CC21CC1=CC=CC=C1 LXEDKSZTPGCEPU-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- YDCVQGAUCOROHB-UHFFFAOYSA-N oxadiazolidine-4,5-dione Chemical class O=C1NNOC1=O YDCVQGAUCOROHB-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- VWMZIGBYZQUQOA-QEEMJVPDSA-N pamaqueside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC(=O)[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWMZIGBYZQUQOA-QEEMJVPDSA-N 0.000 description 1
- 229950005482 pamaqueside Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 229950004437 tiqueside Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Description
1 NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE Description 5 Benzotriazoles are already known from a wide range of fields, such as for example photochemistry (US 4,255,510, Kodak) or as orexin antagonists (WO 02/090355, SKB). Also, the synthesis for preparing benzotriazoles has been described by Katritzky et al. in J. Org. Chem. 1997, 62, 4155 4158. Also known are carbamates for use as lipase inhibitors such as for 10 example Shamkant Patkar et al. in Paul Woolley, Steffen B. Petterson (ed), Lipase (1994) 207-227 or WO 03/051842. Surprisingly, it has now been possible to show that the benzotriazoles of the present invention show activity with regard to HSL, hormone sensitive 15 lipase. In a first aspect the invention relates to benzotriazoles of the formula I, R1 R2 N N N R3 R4 N ()n R8 0 R7 R5 R6 20 in which the meanings are: R1 to R8 H, where one of these radicals R2 or R3 may represent: Br, Cl, CH 3 , CN, NH 2 , NO 2 , CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH) 25 phenyl, S-cyclohexyl, CO-OCH 3 ; or 2 two substituents of this series are: R1 = Ci and R3 CF 3 or R2 = F and R3 Cl; n an integer from 0, 1 or 2; and 5 one of the substituents R6 or R7 may represent R6 CH 3 ; R7 CH 3 , C 2
H
5 ; CH(CH 3
)
2 , C(CH3)3, CF 3 , Br, Cl, benzyl or
CO-OC
2
H
5 ; or R6 and R7 are both CH 3 ; or 10 the ring may contain a double bond instead of R6 and R7 or R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring or else if n = 0 may represent cyclohexanediyl; where in the case of the R6/R7 ring closure this substituent may be optionally 15 substituted singly by NH 2 or NO 2 or singly or doubly by
OCH
3 ; and R7 and R8 together cyclopentyl, diazirine or =CH 2 ; where the compounds with R1 to R5 and R8 = H, n = 1 and RG/R7 20 benzo-fused and R1, R3-R8 - H , R2 = CH 3 and n = I shall be excluded. In a second aspect of the invention there is provided a benzotriazole of the formula I, R1 R2 N N R3 : 2K / R8 R4 I 0 R7 R5 R6 25 in which the meanings are: Rl to R8 H; 2a where one of these radicals R2 or R3 may represent: Br, Cl, CH 3 , CN, NH 2 , NO 2 , CF 3 , OCH3, phenoxy, benzoyl, CH(OH) phenyl, S-cyciohexyl, CO-OCH 3 ; or 5 two substituents of this series are: R1 = Cl and R3 CF 3 or R2 = F and R3 = Cl; n an integer from 0, 1 or 2; and one of the substituents R6 or R7 may represent: 10 R6
CH
3 ; R7 CH 3 , C2H; CH(CH 3
)
2 , C(CH 3
)
3 , CF 3 , Br, Cl, benzyl or
CO-OC
2
H
5 ; or R6 and RWare both CH 3 ; or the ring may contain a double bond instead of R6 and R7 or 15 R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring or else if n = 0 may represent cyclohexanediyl; where in the case of the R6/R7 ring closure this substituent may be optionally substituted singly by NH 2 or NO 2 or singly or doubly by 20
OCH
3 ; and R7 and R8 together cyclopentyl, diazirine or =CH 2 ; for use in the manufacture of a medicament, for use in inhibiting hormone sensitive lipase, HSL, for the treatment of a disease selected from the group consisting of non-insulin dependent diabetes mellitus, diabetes 25 syndrome or syndrome X. The invention relates to compounds of the formula I in the form of their racemates, racemic mixtures and pure enantiomers and to their diastereomers and mixtures thereof. 30 The alkyl radicals may be either straight-chain or branched. Halogen is fluorine, chlorine or bromine, in particular fluorine or chlorine.
2b Preference is given to benzotriazoles of the formula I in which the meanings are: R1 to R8 H; where one of these radicals R2 or R3 may represent: 3 R2 Br, Cl, CN, NO 2 , CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH)-phenyl, S-cyclohexyl,
CO-OCH
3 ; R3 CH 3 , CN, Br, Cl, NH 2 , NO 2 , benzoyl. 5 Particular preference is given to the benzotriazoles of the formula I in which the meanings are: R1 to R8 H; where one of these radicals R2 or R3 may represent: 10 R2 Br, Cl, NO 2 , OCH 3 , phenoxy, CO-OCH 3 ; R3 NH 2 ; or two substituents of this series are: R2 = F and R3 = Cl; n an integer from 1 or 2; and 15 one of the substituents R5 or R6 may represent: R6
CH
3 ; R7 CH 3 , CF 3 or Br; or the ring may contain a double bond instead of R6 and R7 or R6 and R7 may together with the carbon atoms carrying them represent a 20 benzo-fused ring which may optionally be substituted singly by NH 2 or singly or doubly by OCH 3 ; and R7 and R8 together cyclopentyl or n an integer from 0; and R6 and R7 may together with the carbon atoms carrying them represent a 25 benzo-fused ring or cyclohexanediyl; or benzotriazoles of the formula I in which R1 to R8 H; 30 where one of these radicals R2 or R3 may represent: R2 Br, CN, CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH) phenyl, S-cyclohexyl; 4 R3 CN, Br, CI, NO 2 , benzoyl; or two substituents of this series are: R1 = Cl and R3 = CF 3 ; n an integer from 1; and 5 one of the substituents R6 and R7 may represent: R6
CH
3 ; R7
CH
3 , C 2
H
5 ; CH(CH 3
)
2 , C(CH 3
)
3 , benzyl or CO-OC 2
H
5 ; or R6 and R7 are both CH 3 ; or 10 the ring may contain a double bond instead of R6 and R7 or R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring; where the compounds with R1 to R5 and R8 = H, n = 1 and R6/R7 = 15 benzo-fused shall be excluded. Very particular preference is given to the benzotriazoles of the following structures: N H-1C'O N 0O O N
CH
3 20 -~N N 0 N C N ON \ O N N oN CH3 /N O N N N 0 /'o -4 CI N 6 N ONN 0 NAN 0 NO N N 0Q N N N-N 5 0 Br N N F 0 Br F4 NA N- P F r N B r N-N &I.0 7 N O N CCN
NH
2 N 0 c H3C-O N 3O N
H
3 C O NCH O/N H2N N N CH 3 CNN C N / CH 3 N OH 3 CI "j) N / 0,N 8 N N :N N NN N or the benzotriazoles of the following structures: 5 N N CCN 0'
CH
3 ONN -NI ,+[: N NN CH3 o:N /N
CH
3 /' N0 N OH 0O 0 9 N INN N CH 3 CCN3 O N C ,N :NO N CN CH 3 O N 0 i N N N H//\ No N~NN N /OH 3 N 56 N 0 OH 3 CH 3 10 0 N O NC N N CH 3 Br NN N OCH 3 F F N N H 0
H
3 N Br N N (: N OH H 3 O OH N. N 5 0~ O-H 3 N.0 N N I- N
CH
3 N
CH
3 0 CH 3 N. \ N N~ / Na N N. N :N 00 12 0 Br N ' N-N
OH
3 0 NN N /\ F -b F N F/ _ N % N0 NN CI N F N F 13 CN N 0NCa 0,CH 3 'o
H
3 C 'NIC N N 0 O
CH
3 OIZ N N NZ% o ~ 0
-~-CH
3 00 N NIC C 1 N :N/ O Na 14 : N N O No 0/ Very particular preference is further given to benzotriazoles of the following structures: 5 N O N 0
CH
3 N N I I N :N/ N N 10
N
15 O N N N
CH
3 :~ N N H 0
OH
3
OH
3 N O:~N/ -N CH 3
CH
3
H
3 0 CI N N 6 C
OH
3
OH
3 N 01 Na 5 0>~
OH
3 16 N , N CN 0/ -No s0,CH3 00 C N N oN N CH3 // N N 0 O- H 3 17 N O/\N HCH 3 H3C N N CH 3
CH
3 N O\ NCH CN/ 0
OH
3 N 5 N N N OCH3 Pharmaceutically acceptable salts are, because their solubility in water is greater than that of the initial or basic compounds, particularly suitable for 10 medical applications. These salts must have a pharmaceutically 18 acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid, and of organic acids such as, for 5 example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic and tartaric acid. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts 10 (such as magnesium and calcium salts), trometamol (2-amino-2 hydroxymethyl-1,3-propanediol), diethanolamine, lysine or ethylenediamine. Salts with a pharmaceutically unacceptable anion such as, for example, 15 trifluoroacetate likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications. 20 The term "physiologically functional derivative" used herein refers to any physiologically tolerated derivative of a compound of the formula I of the invention, for example an ester, which on administration to a mammal such as, for example, a human is able to form (directly or indirectly) a compound of the formula I or an active metabolite thereof. 25 Physiologically functional derivatives also include prodrugs of the compounds of the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may themselves be 30 active or not.
19 The compounds of the invention may also exist in various polymorphous forms, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention. 5 All references to "compound(s) of formula I" hereinafter refer to compound(s) of the formula I as described above, and their salts, solvates and physiologically functional derivatives as described herein. 10 The compound(s) of formula (1) may also be administered in combination with other active ingredients. The amount of a compound of formula I necessary to achieve the desired biological effect depends on a number of factors, for example the specific 15 compound chosen, the intended use, the mode of administration and the clinical condition of the patient. The daily dose is generally in the range from 0.3 mg to 100 mg (typically from 3 mg and 50 mg) per day and per kilogram of bodyweight, for example 3-10 mg/kg/day. An intravenous dose may be, for example, in the range from 0.3 mg to 1.0 mg/kg, which can 20 suitably be administered as infusion of 10 ng to 100 ng per kilogram and per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter. Single doses may contain, for example, from 1 mg to 10 g of the active ingredient. Thus, ampoules for injections may contain, for example, from 1 25 mg to 100 mg, and single-dose formulations which can be administered orally, such as, for example, capsules or tablets, may contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg. For the therapy of the abovementioned conditions, the compounds of formula I may be used as the compound itself, but they are preferably in the form of 30 a pharmaceutical composition with an acceptable carrier. The carrier must, of course, be acceptable in the sense that it is compatible with the other ingredients of the composition and is not harmful for the patient's health.
20 The carrier may be a solid or a liquid or both and is preferably formulated with the compound as a single dose, for example as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient. Other pharmaceutically active substances may likewise be present, including 5 other compounds of formula 1. The pharmaceutical compositions of the invention can be produced by one of the known pharmaceutical methods, which essentially consist of mixing the ingredients with pharmacologically acceptable carriers and/or excipients. 10 Pharmaceutical compositions of the invention are those suitable for oral, rectal, topical, peroral (for example sublingual) and parenteral (for example subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration depends in each individual case on the nature and severity of the condition to be 15 treated and on the nature of the compound of formula I used in each case. Coated formulations and coated slow-release formulations also belong within the framework of the invention. Preference is given to acid- and gastric juice-resistant formulations. Suitable coatings resistant to gastric juice comprise cellulose acetate phthalate, polyvinyl acetate phthalate, 20 hyd roxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate. Suitable pharmaceutical compounds for oral administration may be in the form of separate units such as, for example, capsules, wafers, suckable 25 tablets or tablets, each of which contain a defined amount of the compound of formula I; as powders or granules, as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. These compositions may, as already mentioned, be prepared by any suitable pharmaceutical method which includes a step in which the 30 active ingredient and the carrier (which may consist of one or more additional ingredients) are brought into contact. The compositions are generally produced by uniform and homogeneous mixing of the active 21 ingredient with a liquid and/or finely divided solid carrier, after which the product is shaped if necessary. Thus, for example, a tablet can be produced by compressing or molding a powder or granules of the compound, where appropriate with one or more additional ingredients. 5 Compressed tablets can be produced by tableting the compound in free flowing form such as, for example, a powder or granules, where appropriate mixed with a binder, glidant, inert diluent and/or one (more) surface-active/dispersing agent in a suitable machine. Molded tablets can be produced by molding the compound, which is in powder form and is 10 moistened with an inert liquid diluent, in a suitable machine. Pharmaceutical compositions which are suitable for peroral (sublingual) administration comprise suckable tablets which contain a compound of formula I with a flavoring, normally sucrose and gum arabic or tragacanth, 15 and pastilles which comprise the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic. Pharmaceutical compositions suitable for parenteral administration comprise preferably sterile aqueous preparations of a compound of 20 formula I, which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although administration may also take place by subcutaneous, intramuscular or intradermal injection. These preparations can preferably be produced by mixing the compound with water and making the resulting 25 solution sterile and isotonic with blood. Injectable compositions of the invention generally contain from 0.1 to 5% by weight of the active compound. Pharmaceutical compositions suitable for rectal administration are 30 preferably in the form of single-dose suppositories. These can be produced by mixing a compound of the formula I with one or more 22 conventional solid carriers, for example cocoa butter, and shaping the resulting mixture. Pharmaceutical compositions suitable for topical use on the skin are 5 preferably in the form of ointment, cream, lotion, paste, spray, aerosol or oil. Carriers which can be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active ingredient is generally present in a concentration of from 0.1 to 15% by weight of the composition, for example from 0.5 to 2%. 10 Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal uses can be in the form of single plasters which are suitable for long-term close contact with the patient's epidermis. Such plasters suitably contain the active ingredient in an aqueous solution which 15 is buffered where appropriate, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%. A particular possibility is for the active ingredient to be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 20 2(6): 318 (1986). Further active ingredients suitable for combination products are: all antidiabetics mentioned in the Rote Liste 2001, chapter 12. They may be combined with the compounds of the formula I of the invention in 25 particular for a synergistic improvement of the effect. Administration of the active ingredient combination may take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. Most of the active ingredients listed 30 below are disclosed in the USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001.
23 Antidiabetics include insulin and insulin derivatives such as, for example, Lantus* (see www.lantus.com) or HMR 1964, fast-acting insulins (see US 6,221,633), GLP-1 derivatives such as, for example, those disclosed in WO 98/08871 of Novo Nordisk A/S, and orally effective hypoglycemic 5 active ingredients. The orally effective hypoglycemic active ingredients include, preferably, sulfonylureas, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 10 agonists, potassium channel openers such as, for example, those disclosed in WO 97/26265 and WO 99/03861 of Novo Nordisk A/S, insulin sensitizers, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, compounds which alter lipid metabolism, such as antihyperlipidemic active 15 ingredients and antilipidemic active ingredients, compounds which reduce food intake, PPAR and PXR agonists and active ingredients which act on the ATP-dependent potassium channel of the beta cells. In one embodiment of the invention, the compounds of the formula I are 20 administered in combination with an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin. In one embodiment of the invention, the compounds of the formula I are 25 administered in combination with a cholesterol absorption inhibitor such as, for example, ezetimibe, tiqueside, pamaqueside. In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR gamma agonist, such as, for 30 example, rosiglitazone, pioglitazone, JTT-501, GI 262570.
24 In one embodiment of the invention, the compounds of the formula I are administered in combination with a PPAR alpha agonist, such as, for example, GW 9578, GW 7647. 5 In one embodiment of the invention, the compounds of the formula I are administered in combination with a mixed PPAR alpha/gamma agonist, such as, for example, GW 1536, AVE 8042, AVE 8134, AVE 0847, or as described in WO 00/64888, WO 00/64876, WO 03/020269. 10 In one embodiment of the invention, the compounds of the formula I are administered in combination with a fibrate such as, for example, fenofibrate, clofibrate, bezafibrate. In one embodiment of the invention, the compounds of the formula I are 15 administered in combination with an MTP inhibitor such as, for example, implitapide, BMS-201038, R-103757. In one embodiment of the invention, the compounds of the formula I are administered in combination with bile acid absorption inhibitor (see, for 20 example, US 6,245,744 or US 6,221,897), such as, for example, HMR 1741. In one embodiment of the invention, the compounds of the formula I are administered in combination with a CETP inhibitor, such as, for example, 25 JTT-705. In one embodiment of the invention, the compounds of the formula I are administered in combination with a polymeric bile acid adsorbent such as, for example, cholestyramine, colesevelam. 30 25 In one embodiment of the invention, the compounds of the formula I are administered in combination with an LDL receptor inducer (see US 6,342,512), such as, for example, HMR1 171, HMR1586. 5 In one embodiment of the invention, the compounds of the formula I are administered in combination with an ACAT inhibitor, such as, for example, avasimibe. In one embodiment of the invention, the compounds of the formula I are 10 administered in combination with an antioxidant, such as, for example, OPC-14117. In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein lipase inhibitor, such as, for 15 example, NO-1886. In one embodiment of the invention, the compounds of the formula I are administered in combination with an ATP-citrate lyase inhibitor, such as, for example, SB-204990. 20 In one embodiment of the invention, the compounds of the formula I are administered in combination with a squalene synthetase inhibitor, such as, for example, BMS-1 88494. 25 In one embodiment of the invention, the compounds of the formula I are administered in combination with a lipoprotein(a) antagonist, such as, for example, C1-1027 or nicotinic acid. In one embodiment of the invention, the compounds of the formula I are 30 administered in combination with a lipase inhibitor, such as, for example, orlistat.
26 In one embodiment of the invention, the compounds of the formula I are administered in combination with insulin. In one embodiment, the compounds of the formula I are administered in combination with a sulfonylurea such as, for example, tolbutamide, 5 glibenclamide, glipizide or glimepiride. In one embodiment, the compounds of the formula I are administered in combination with a biguanide, such as, for example, metformin. In one further embodiment, the compounds of the formula I are 10 administered in combination with a meglitinide, such as, for example, repaglinide. In one embodiment, the compounds of the formula I are administered in combination with a thiazolidinedione, such as, for example, troglitazone, 15 ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[{4-[(3,4 dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2,4 thiazolidinedione. 20 In one embodiment, the compounds of the formula I are administered in combination with an a-glucosidase inhibitor, such as, for example, miglitol or acarbose. In one embodiment, the compounds of the formula I are administered in 25 combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide. In one embodiment, the compounds of the formula I are administered in 30 combination with more than one of the aforementioned compounds, e.g. in 27 combination with a sulfonylurea and metformin, with a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc. 5 In a further embodiment, the compounds of the formula I are administered in combination with CART modulators (see "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A, et al., M.: Hormone and Metabolic Research (2001), 33(9), 554-558), NPY antagonists, e.g. naphthalene-1-sulfonic acid {4-[(4 10 aminoquinazolin-2-ylamino)methyl]- cyclohexylmethyl}amide hydrochloride (CGP 71683A)), MC4 agonists (e.g. 1-amino-1,2,3,4-tetrahydronaphthalene 2-carboxylic acid [2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7 hexahydropyrazolo[4,3-c]pyridin-5-yl)-1 -(4-chlorophenyl)-2-oxoethyl]-amide; (WO 01/91752)), orexin antagonists (e.g. 1-(2-methylbenzoxazol-6-yl)-3 15 [1,5]naphthyridin-4-ylurea hydrochloride (SB-334867-A)), H3 agonists (3-cyclohexyl-1 -(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin 5-yl)propan-1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren 4-yl]dipropylamine (WO 00/66585)), CRF BP antagonists (e.g. urocortin), 20 urocortin agonists, p3 agonists (e.g. 1-(4-chloro-3-methanesulfonylmethyl pheny)-2-[2-(2,3-dimethyl-1 H-indol-6-yloxy)ethylamino]-ethanol hydrochloride (WO 01/83451)), MSH (melanocyte-stimulating hormone) agonists, CCK-A agonists (e.g. {2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2 cyclohexylethyl)thiazol-2-ylcarbamoyl]-5,7-dimethylindol-1 -yl}acetic acid 25 trifluoroacetic acid salt (WO 99/15525)), serotonin reuptake inhibitors (e.g. dexfenfluramine), mixed sertoninergic and noradrenergic compounds (e.g. WO 00/71549), 5HT agonists e.g. 1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01/09111), bombesin agonists, galanin antagonists, growth hormone (e.g. human growth hormone), growth hormone-releasing 30 compounds (6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro 1H-isoquinoline-2-carboxylic acid tertiary butyl ester (WO 01/85695)), TRH agonists (see, for example, EP 0 462 884), uncoupling protein 2 or 3 28 modulators, leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881), DA agonists (bromocriptine, Doprexin), 5 lipase/amylase inhibitors (e.g. WO 00/40569), PPAR modulators (e.g. WO 00/78312), RXR modulators or TR-p agonists. In one embodiment of the invention, the other active ingredient is leptin; see, for example, "Perspectives in the therapeutic use of leptin", Salvador, 10 Javier; Gomez-Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy (2001), 2(10), 1615-1622. In one embodiment, the other active ingredient is dexamphatamine or amphetamine. 15 In one embodiment, the other active ingredient is fenfluramine or dexfenfluramine. In another embodiment, the other active ingredient is sibutramine. In one embodiment, the other active ingredient is orlistat. In one embodiment, the other active ingredient is mazindol or 20 phentermine. In one embodiment, the compounds of the formula I are administered in combination with bulking agents, preferably insoluble bulking agents (see, for example, carob/Caromax* (Zunft H J; et al., Carob pulp preparation for 25 treatment of hypercholesterolemia, ADVANCES IN THERAPY (2001 Sep Oct), 18(5), 230-6.) Caromax is a carob-containing product from Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark H6chst, 65926 Frankfurt/Main)). Combination with Caromax* is possible in one preparation or by separate administration of compounds of the 30 formula I and Caromax*. Caromax* can in this connection also be administered in the form of food products such as, for example, in bakery products or muesli bars.
29 It will be appreciated that every suitable combination of the compounds of the invention with one or more of the aforementioned compounds and optionally one or more other pharmacologically active substances is 5 regarded as falling within the protection conferred by the present invention.
30
CH
3
CH
3 0 N : 0CH 3 OH HN)N o NH 3 C OH 3
OCH
3 CH 3 OPC-14117 0
CH
3 JTT-705 Cl BrC1 N SB-204990 HO HO C I 10~ CH 3 N NO-1886 O OH HC CH 3
H
3 C
CH
3 0 C1-1027 O H 3 C CH 3 BMS-188494 O 0 0
OH
3 OH 0 N 0 N O0
OH
3 O .O G1262570 JTT-501 The benzotriazoles of the invention of the formula I are prepared by methods which are known per se, e.g. by acylation of substituted or 5 unsubstituted benzotriazole 2 with carbamoyl chlorides 3 (method A), or in 31 two stages by reacting benzotriazoles with phosgene and further reaction of the resulting benzotriazolecarbonyl chloride with amines or anilines (method B). R1 cl R1 ' N + N 80 R N oR7 N R3 N / R5q R3 N () R4 R6 R4 -N( R8 0 R7 R5 R6 5 2 R1 ci RI N /(nR R2 N + cl R2 N R7 N 1 N R5 R R3 N N R3 N R6 R4 R4 Cl 2 5 Since acids are usually liberated in these reactions, it is advisable to add 10 bases such as pyridine, triethylamine, sodium hydroxide solution or alkali metal carbonates to increase the rate. The reactions can be carried out in wide temperature ranges. It has usually proved to be advantageous to operate at from 00C to the boiling point of the solvent used. Examples of solvents employed are methylene chloride, THF, DMF, toluene, ethyl 15 acetate, nheptane, dioxane, diethyl ether. The compounds of the invention of the formula I have a surprising inhibitory effect on hormone-sensitive lipase, HSL, an allosteric enzyme in adipocytes, which is inhibited by insulin and is responsible for the 32 breakdown of fats in fat cells and thus for the transfer of constituents of fats into the bloodstream. Inhibition of this enzyme thus corresponds to an insulin-like effect of the compounds of the invention, which eventually leads to a reduction of free fatty acids in the blood and of blood glucose. 5 They can thus be employed in metabolic derangements such as, for example, in non-insulin-dependent diabetes mellitus, in diabetic syndrome, in syndrome X and in direct pancreatic damage. An inhibition of HSL in beta cells should lead to a direct recovery of insulin release (M. Winzell et al., Diabetes, Vol 52, August 2003, 2057-2065). The 10 compounds of formula I according to the present invention can therefore also be used for insulin release. Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated 15 features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof. The effect of the compounds of the invention of the formula I was tested in 20 the following enzyme assay system: Substrate preparation: Preparation of NAG (NBD monoacyl glyceride) substrate: 25 6 mg of phosphatidylcholine and 6 mg of phosphatidylinositol are each dissolved in 1 ml of chloroform. 10 mg of NAG are dissolved in 1 ml of chloroform. Two parts of phosphatidylinositol solution (e.g. 83.5 pl) and one part of phosphatidylcholine solution (e.g. 41.5 il) and 100 Id of NAG solution are pipetted together into plastic scintillation vessels (final 30 concentration in the assay: 0.0375 mg of phospholipid/ml; 0.05 mg/NAG/ml). The chloroform (225 Il total volume) is completely removed by passing a stream of N2 over. The dried substrate can be 32a stored at 4 0 C for up to 3 days. To prepare the phospholipid vesicles/micelles with intercalated NAG (on the day of the assay), the dried substrate is taken up in 20 ml of assay buffer (25 mM Tris/HCI, pH 7.4; 150 mM NaCl) and [lacuna] two ultrasound treatments with an 5 ultrasonic probe (Branson Sonifier Type 1l, standard microtip): 1st treatment setting 2, 2 x 1 min, inbetween 1 min on ice each time; 2nd 33 treatment setting 4, 2 x 1 min, inbetween 1 min on ice each time. During this procedure, the color of the substrate solution changes from yellow (extinction maximum 481 nm) to red (extinction maximum 550 nm) owing to intercalation of NAG between the phospholipid molecules in the 5 vesicles/micelles. Before use as substrate (within the next 2 h), the solution is incubated on ice for a further 15 min. Indirect NAG assay: 10 The assay is carried out in 1.5 ml Eppendorf vessels or 96-well plates at 300C for 60 min. To find HSL inhibitors, 10 pl of the test substance are introduced into assay buffer (25 mM Tris/HCI, pH 7.4; 150 mM NaCI) in the presence of 16.6% DMSO. 180 pi of the substrate solution (20 pig/ml phosphatidylcholine, 10 pg/ml phosphatidylinositol, 50 pg/ml NAG in assay 15 buffer) are added. After preincubation at 300C for 15 min, 20 pi of the enzyme solution in assay buffer (diluted 1- to 4-fold are pipetted in, and the extinction at 480 nm is immediately measured in a cuvette photometer (0.5 ml cuvette) or microtiter plate reader. After incubation at 300C for 60 min, the extinction is measured again. The increase in extinction at 20 480 nm is a measure of the enzymic activity. Under standard conditions, 20 pg of partially purified HSL lead to a change of 0.4 = 4000 arb. units in extinction. Direct NAG assay: 25 As alternative to measurement of the change in extinction of the substrate solution, the products of the HSL reaction are investigated by phase separation/thin-layer chromatography. For this purpose, 1.3 ml of methanol/chloroform/heptane (10:9:7) and then 0.4 ml of 0.1 M NaOH are 30 added to the incubation mixture (200 pl total volume, see indirect NAG assay) in 2 ml Eppendorf vessels. After vigorous mixing (10 sec), phase separation is initiated by centrifugation (800xg, 20 min, room 34 temperature). Equivalent volumes (e.g. 0.4 ml) are taken from the aqueous upper phase, and the extinction at 481 nm is determined in a photometer. For thin-layer chromatography, the aqueous phase is dried (SpeedVac) and then taken up in 50 pl of tetrahydrofuran. 5 pl samples 5 are loaded onto silica gel Si-60 plates (Merck). The chromatography is carried out with 78 ml of diethyl ether/22 ml of petroleum ether/1 ml of glacial acetic acid as mobile phase. The amount of liberated fluorescent NBD-fatty acid is determined by Phosphorimaging (Molecular Dynamics, Storm 840 and ImageQuant Software) at an excitation wavelength of 10 460 nm and emission wavelength of 540-560 nm. Enzyme preparation: Preparation of the partially purified HSL: 15 Isolated rat fat cells are obtained from epididymal adipose tissue from untreated male rats (Wistar, 220-250 g) by collagenase treatment in accordance with published methods (e.g. S. Nilsson et al., Anal. Biochem. 158, 1986, 399-407; G. Fredrikson et al., J. Biol. Chem. 256, 1981, 6311-6320; H. Tornquist et al., J. Biol. Chem. 251, 1976, 813-819). The fat 20 cells from 10 rats are washed three times by flotation with 50 ml of homogenization buffer (25 ml Tris/HCI, pH 7.4, 0.25 M sucrose, 1 mM ETDA, 1 mM DTT, 10 jig/ml leupeptin, 10 ptg/mI antipain, 20 ig/ml pepstatin) each time and finally taken up in 10 ml of homogenization buffer. The fat cells are homogenized in a Teflon-in-glass homogenizer 25 (Braun-Melsungen) by 10 strokes at 1500 rpm and 15*C. The homogenate is centrifuged (Sorvall SM24 tubes, 5000 rpm, 10 min, 4*C). The subnatant between the layer of fat at the top and the pellet is removed and the centrifugation is repeated. The subnatant resulting therefrom is centrifuged again (Sorvall SM24 tubes, 20 000 rpm, 45 min, 40C). The 30 subnatant is removed, and 1 g of heparin-Sepharose (Pharmacia-Biotech, CL-6B, washed 5x with 25 mM Tris/HCI, pH 7.4, 150 mM NaCI) is added. After incubation at 4*C for 60 min (shaking at intervals of 15 min), the 35 mixture is centrifuged (Sorvall SM24 tubes, 3000 rpm, 10 min, 4"C). The supernatant is adjusted to pH 5.2 by adding glacial acetic acid and is incubated at 40C for 30 min. The precipitates are collected by centrifugation (Sorvall SS34, 12 000 rpm, 10 min, 40C) and suspended in 5 2.5 ml of 20 mM Tris/HCI, pH 7.0, 1 mM EDTA, 65 mM NaCl, 13% sucrose, 1 mM DTT, 10 pg/ml leupeptin/pepstatin/antipain. The suspension is dialyzed against 25 mM Tris/HCI, pH 7.4, 50% glycerol, 1 mM DTT, 10 ig/ml leupeptin, pepstatin, antipain at 4*C overnight and then loaded onto a hydroxiapatite column (0.1 g per 1 ml of suspension, 10 equilibrated with 10 mM potassium phosphate, pH 7.0, 30% glycerol, 1 mM DTT). The column is washed with four volumes of equilibration buffer at a flow rate of 20 to 30 ml/h. The HSL is eluted with one volume of equilibration buffer containing 0.5 M potassium phosphate and then dialyzed (see above) and concentrated 5- to 10-fold by ultrafiltration 15 (Amicon Diaflo PM 10 Filter) at 40C. The partially purified HSL can be stored at -700C for 4 to 6 weeks. Assay: 20 To prepare the substrate, 25-50 pCi of [3H]trioleoylglycerol (in toluene), 6.8 ptmol of unlabeled trioleoylglycerol and 0.6 mg of phospholipids (phosphatidylcholine/phosphatidylinositol 3:1 w/v) are mixed, dried over N2 and then taken up in 2 ml of 0.1 M KPi (pH 7.0) by ultrasound treatment (Branson 250, microtip, setting 1-2, 2 x 1 min with an interval of 25 1 min). After addition of 1 ml of KPi and renewed ultrasound treatment (4 x 30 sec on ice with intervals of 30 sec), 1 ml of 20% BSA (in KPi) is added (final concentration of trioleoylglycerol 1.7 mM). For the reaction, 100 [il of substrate solution are pipetted into 100 pl of HSL solution (HSL prepared as above, diluted in 20 mM KPi, pH 7.0, 1 mM EDTA, 1 mM 30 DTT, 0.02% BSA, 20 ptg/ml pepstatin, 10 pg/ml leupeptin) and incubated at 370C for 30 min. Addition of 3.25 ml of methanol/chloroform/heptane (10:9:7) and of 1.05 ml of 0.1 M K2CO3, 0.1 M boric acid (pH 10.5) is 36 followed by thorough mixing and finally centrifugation (800 x g, 20 min). After phase separation, one equivalent of the upper phase (1 ml) is removed and the radioactivity is determined by liquid scintillation measurement. 5 Evaluation: Substances are normally tested in four independent mixtures. The inhibition of the HSL enzymatic activity by a test substance is determined 10 by comparing with an uninhibited control reaction. The IC50 is calculated from an inhibition plot with min. 10 concentrations of the test substance. The GRAPHIT, Elsevier-BIOSOFT software package is used to analyze the data. 15 The compounds of Examples 1 to 55 showed inhibitions in the IC50 range 0.04-5 ptM in this assay. The following example describe the invention in more detail without restricting it. 20 Examples: The example which follow were prepared according to the methods described in what follows: 25 Method A: To a solution of 2 mmol of 1H-benzotriazole in pyridine (5 ml) and dichloromethane (10 ml) is added a solution of the corresponding carbamoyl chloride (1 mmol) in dichloromethane (10 ml). The reaction mixture is stirred at RT for 16 h, then admixed with EtOAc (15 ml), and 30 filtered through silica gel before the filtrate is concentrated. The product is purified by preparative HPLC and freeze dried.
37 Method B Examples: a) Preparation of a benzotriazole-1-carbonyl chloride solution A solution of benzotriazole (6 g, 50.4 mmol) in THF (100 ml) is added dropwise to a phosgene solution (20% in toluene; 90 ml; 182 mmol) while 5 cooling in ice. The ice bath is removed and the solution is then stirred at RT for a further 2 h. The solvent is distilled out and the residue is taken up in THF to give a total volume of 25 ml. b) Reaction of the benzotriazolecarbonyl chlorides to give the 10 corresponding benzotriazole-1 -carboxamides and anilides In each case 10 amines or anilines (2 mmol) are introduced into THF (1 ml), and pyridine (0.2 ml) is added. The mixtures are incubated with benzotriazole-1-carbonyl chloride solution (1 ml, - 2 mmol) and stirred at RT for 16 h. The mixtures are then diluted with ethyl acetate (5 ml) and 15 filtered through silica gel, and the filtrate is evaporated to dryness in vacuo. The crude products are purified by flash chromatography. Example 1: Methyl 3-(4-methylpiperidine-1-carbonyl)-3H-benzotriazole-5-carboxylate 20 N ' /N H 3C-O -0 N 0 O N
CH
3 M+H+: 303.14 38 Example 2: (8-Aza-spiro[4.5]dec-8-y)-benzotriazol-1 -ylmethanone N N 5 M+H+: 285.16 Example 3: Benzotriazol-1 -yl-(6,7-dimethoxy-3,4-dihydro-1 H-isoquinolin-2-yl) 10 methanone N N 0 M+H+: 339.13 15 39 Example 4: (5-Phenoxybenzotriazol-1 -yl)-(4-trifluoromethylpiperidin-1 -yl)methanone 0 N O NF F 5 M+H+: 391.13 Example 5: (6-Chloro-5-fluorobenzotriazol-1 -yl)-(4-methylpiperidin-1 -yl)methanone 10 F N N O0 N CH3 M+H+:297.74 15 Example 6: Benzotriazol-1 -yl-(4-bromopiperidin-1 -yl)methanone ,N 0 Br M+H+: 310.3 20 40 Example 7: Benzotriazol-1 -yl-(4-trifluoromethylpiperidin-1 -yl)methanone N O N FF F 5 M+H+: 299.18 Example 8: Benzotriazol-1 -yl-(1,3-dihydroisoindol-2-yl)methanone N N 10 M+H+: 265.0 Example 9: Methyl 1-(3,6-dihydro-2H-pyridine-1 -carbonyl)-1 H-benzotriazole 15 5-carboxylate 0 O-CH3 N 0 N==N M+H+: 287.04 20 41 Example 10: (3,6-Dihydro-2H-pyridin-1 -yl)-(5-nitrobenzotriazol-1 -yl)methanone 0 N N 5 M+Na: 296.21 Example 11: (3,4-Dihydro-1 H-isoquinolin-2-yl)-(5-nitrobenzotriazol-1 -yl)methanone 10 0 N NO N N M+H+: 324.10 15 Example 12: (5-Bromobenzotriazol-1 -yl)-(3,6-dihydro-2H-pyridin-1 -yl)methanone N Br NaN 20 M+H+: 306.98 42 Example 13: (5-Bromobenzotriazol-1 -yI)-(3-trifluoromethylpiperidin-1 -yl)methanone F 0 Br F4 N N / Br F r NzzN 5 M+H+: 377.30 Example 14: (5-Bromobenzotriazol-1 -yl)-(3,4-dihydro-1 H-isoquinolin-2-yl)methanone 0 Br N N N-N 10 M+H+: 357.04 Example 15: 15 Benzotriazol-1 -yl-(octahydroisoindol-2-yl)methanone N N M+H+: 271.15 20 43 Example 16: (7-Amino-3,4-dihydro-1 H-isoquinolin-2-yl)benzotriazol-1 -ylmethanone N N 5 M+H+: 294.0 Example 17: (3,4-Dihydro-1 H-isoquinolin-2-yl)-(5-methoxybenzotriazol-1 -yl)methanone 10
H
3 C -O N ,N N oN O C M+H+: 309.04 15 Example 18: (5-Methoxybenzotriazol-1 -yl)-(3-methylpiperidin-1 -yl)methanone C0 N N N
CH
3 O+ N 20 M+H+: 275.5 44 Example 19: (6-Aminobenzotriazol-1 -yl)-(4-methylpiperidin-1 -yl)methanone -, N N
H
2 N N o O H 3 5 M+H+: 260.1 Example 20: 10 (5-Chlorobenzotriazol-1-yl)-(4-methylpiperidin-1-yl)methanone Cl -,N\ CN O N' o O-H 3 M+H+: 279.6 15 Example 21: Benzotriazol-1 -yl-(1,2,6-triaza-spiro[2.5]oct-1 -en-6-yl)methanone N N :NNI/ N M+Na+: 279.19 20 45 Example 22: Benzotriazol-1 -yl-(4-ethylpiperidin-1 -yl)methanone
-
N
CH
3 5 M+H+: 259.04 Example 23: (4-Methylpiperidin-1 -yl)-(6-nitrobenzotriazol-1 -yl)methanone O NN WaN N N 100 M+H+: 290.4 Example 24: 15 Ethyl 1 -(benzotriazole-1 -carbonyl)piperidine-4-carboxylate C N NN CH3 ON (3 0 M+H+: 303.13 46 Example 25: Benzotriazol-1 -yl-(4-methylpiperidin-1 -yl)methanone SN\ N 0 N
CH
3 5 M+H+: 245.0 Example 26: 3-(4-Methylpiperidine-1 -carbonyl)-3H-benzotriazole-5-carbonitrile 10 N N N 0
CH
3 M+H+: 270.12 15 Example 27: Benzotriazol-1 -yl-(3,4-dihydro-1 H-isoquinolin-1 -yl)methanone -~N N N N M+H+: 279.11 20 47 Example 28: Benzotriazol-1 -yl-(3,4-dihydro-2H-quinolin-1 -yl)methanone N N O 5 M+H+: 279.2 Example 29: (6-Methylbenzotriazol-1 -yl)-pyrrolidin-1 -ylmethanone 10 -,N
H
3 0 ~NQ M+H+: 231.11 15 Example 30: Benzotriazol-1 -yl-(3-methylpiperidin-1 -yl)methanone N N ,N
CH
3 M+H+: 245.13 20 48 Example 31: Benzotriazol-1 -yl-(3,4-dimethylpiperidin-1 -yl)methanone N O N - CH 3
CH
3 5 M+H+: 259.14 Example 32: [1 -(4-Methylpiperidine-1 -carbonyl)-1 H-benzotriazol-5-yl]phenylmethanone 0 N /N O CH 3 10 M+H+: 349.15 Example 33: (4-Methylpiperidin-1 -yl)-(5-trifluoromethylbenzotriazol-1 -yl)methanone 15 F F N N H 3 M+H+: 313.5 49 Example 34: (6-Bromobenzotriazol-1 -yl)-(4-methylpiperidin-1 -yl)methanone -N /N Br N 0 O H 3 5 M+H+: 324.0 Example 35: Benzotriazol-1 -yl-(4-tert-butylpiperidin-1 -yl)methanone 10 :~ N N O No _ HH3 H 3C M+H+: 287.17 Example 36: 15 [5-(Hydroxyphenylmethyl)benzotriazol-1 -yl]-(4-methylpiperidin-1 -yl) methanone OH N SN' OkN
CH
3 M+H+: 350.17 50 Example 37: (4-Methylpiperidin-1 -yl)-(5-phenoxybenzotriazol-1 -yl)methanone O N 5 N CH3 M+H+: 337.3 Example 38: (5-Cyclohexylsulfanylbenzotriazol-1 -yl)-(4-methylpiperidin-1 -yl)methanone 10 S N O N CH3 M+H+: 359.17 Example 39: 15 Benzotriazol-1-yl-(4-isopropylpiperidin-1-yl)methanone ' N N N CH 3
CH
3 M+H+: 273.3 20 51 Example 40: (6-Chlorobenzotriazol-1 -yl)-(4-methylpiperidin-1 -yl)methanone / N Cl N 0 N
CH
3 5 M+H+: 279.5 Example 41: Benzotriazol-1 -yl-(6-methoxy-3,4-dihydro-1 H-isoquinolin-2-yl)methanone 10 N ::N /-- -N 0
CH
3 M+H+: 309.3 15 Example 42: Benzotriazol-1 -yl-(4-benzylpiperidin-1 -yl)methanone N N :N /N o-N M+H+: 321.1 20 52 Example 43: (5-Bromobenzotriazol-1 -yl)-(3-methylpiperidin-1 -yl)methanone N Br N-N
CH
3 5 M+H+: 325.31 Example 44: 1-(3,4-Dihydro-1 H-isoquinoline-2-carbonyl)-1 H-benzotriazole-5-carbonitrile N N 10 M+H+: 270.12 Example 45: (4-Chloro-6-trifluoromethylbenzotriazol-1 -yl)-(3,4-dihydro-1 H-isoquinolin 15 2-yl)methanone C! Ii F N F N O M+H+: 381.06 53 Example 46: 1-(3,4-Dihydro-2H-quinoline-1 -carbonyl)-1 H-benzotriazole-5-carbonitrile N .... N-N 5 M+H+: 304.11 Example 47: (4-Chloro-6-trifluoromethylbenzotriazol-1 -yl)-(3,6-dihydro-2H-pyridin- 1 -yl) methanone 10 CI F N, F N F M+H+: 331.04 Example 48: 15 Benzotriazol-1 -yl-(7-methoxy-3,4-dihydro-1 H-isoquinolin-2-yl)methanone N N O N CH3 M+H+: 309.1 54 Example 49: (5-Methoxybenzotriazol-1 -yl)-(4-methylpiperidin-1 -yl)methanone
H
3 C O N 5 O Na
CH
3 M+H+: 275.3 Example 50: (3,4-Dihydro-1 H-isoquinolin-2-yl)-(6-nitrobenzotriazol-1 -yl)methanone 10 ~~ ,N N N~o : 0 NI0 M+H+: 324.3 Example 51: 15 (6-Benzoylbenzotriazol-1 -yl)-(4-methylpiperidin-1 -yl)methanone N I N SN' 0 ON
CH
3 M+H+: 349.15 20 55 Example 52: Benzotriazol-1 -yl-(7-nitro-3,4-dihydro-1 H-isoquinolin-2-yl)methanone N 0 O ^ ON N 5 M+H+: 324.1 Example 53: Azepan-1 -ylbenzotriazol-1 -ylmethanone N N :N/ 10 0 N M+H+: 245.3 Example 54: Benzotriazol-1 -yl-(4-chloropiperidin-1 -yl)methanone 15 0. N :N O NCI M+H+: 265.7 ..
56 Example 55: Benzotriazol-1 -yl-(3,6-dihydro-2H-pyridin-1 -yl)methanone N O N 5 M+H+: 229.2.
Claims (15)
1. A benzotriazole of the formula I, RI R2 N N R3 N (n R8 R4 N 0 R7 R5 R6 5 in which the meanings are: R1 to R8 H, where one of these radicals R2 or R3 may represent: Br, Cl, CH 3 , CN, NH 2 , NO 2 , CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH) phenyl, S-cyclohexyl, CO-OCH 3 ; 10 or two substituents of this series are: R1 = Cl and R3 =CF 3 or R2 = F and R3 = Cl; n an integer from 0, 1 or 2; and 15 one of the substituents R6 or R7 may represent: R6 CH 3 ; R7 CH 3 , C 2 H 5 ; CH(CH 3 ) 2 , C(CH 3 ) 3 , CF 3 , Br, Cl, benzyl or CO-OC 2 H 5 ; or R6 and R7 are both CH 3 ; or 20 the ring may contain a double bond instead of R6 and R7 or R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring or else if n = 0 may represent cyclohexanediyl; where in the case of the R6/R7 ring closure this substituent may be optionally 25 substituted singly by NH 2 or NO 2 or singly or doubly by OCH 3 ; and 58 R7 and R8 together cyclopentyl, diazepine or =CH 2 ; where the compounds with R1 to R5 and R8 = H, n = 1 and R6/R7 = benzo-fused and R1, R3-R8 = H , R2 = CH 3 and n = 1 shall be excluded. 5
2. A benzotriazole of the formula I as claimed in claim 1, RI R2 N N -~N ()n R8 R4 N 0 R7 R5 R6 in which the meanings are: R1 to R8 H; 10 where one of these radicals R2 or R3 may represent: R2 Br, Cl, CN, NO 2 , CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH)-phenyl, S-cyclohexyl, CO-OCH 3 ; R3 CH 3 , CN, Br, Cl, NH 2 , NO 2 , benzoyl. 15 3. A benzotriazole of the formula I as claimed in claim 1 or 2, in which the meanings are: R1 to R8 H; where one of these radicals R2 or R3 may represent: R2 Br, Cl, NO 2 , OCH 3 , phenoxy, CO-OCH 3 ; 20 R3 NH 2 ; or two substituents of this series are: R2 = F and R3 = Cl; n an integer from 1 or 2; and one of the substituents R6 or R7 may represent: 25 R6 CH 3 ; R7 CH 3 , CF 3 or Br; or 59 the ring may contain a double bond instead of R6 and R7 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring which may optionally be substituted singly by NH 2 or singly or doubly by OCH 3 ; and 5 R7 and R8 together cyclopentyl or n is 0; and R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring or cyclohexanediyl. 10 4. A benzotriazole of the formula I as claimed in claims 1 to 2, wherein R1 to R8 H; where one of these radicals R2 or R3 may represent: R2 Br, CN, CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH) 15 phenyl, S-cyclohexyl; R3 CN, Br, Cl, NO 2 , benzoyl; or two substituents of this series are: R1 = Cl and R3 = CF 3 ; n is 1; and 20 one of the substituents R6 and R7 may represent: R6 CH 3 ; R7 CH 3 , C 2 H 5 ; CH(CH 3 ) 2 , C(CH 3 ) 3 , benzyl or CO-OC 2 H 5 ; or R6 and R7 are both CH 3 ; or 25 the ring may contain a double bond instead of R6 and R7 or R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring; where the compounds with R1 to R5 and R8 = H, n = 1 and R6/R7 = 30 benzo-fused shall be excluded. 60
5. A benzotriazole of the following structure: o I~. ,N H 3 C N o N CH 3 C N ON Cr N : N O N FF 0 0 0 '-" N\ N' F F N N 0 O H 3 61 :N N/ N o O Br F N 00 N-N 00 NN 0 N-N 0 Q N' N 62 N Br N N N F Br F )L \Br F4 N N NzN 0Br 5 OL N cN.NNH N 3C NN 5 C. N :/N NH 2 // 0IC H 3 C N ,N 0 o 63 O N H2N N O3 N C H 3 O N C3 0 N H 2N N C OH 3 N N N NN N 0 0
6. A benzotriazole of the following structure: 10 64 N O N 0 CH 3 O0N N NN CHN 0 H 3 OH N 0N CH 3 % N 50 OH 3 CCN 0 N 65 HCN O N CN CH 3 O N N CN CH 3 CH 3 0 C 1N ON N/H COH 3 F N /N ~ N 50 OH 3 66 Br N N CH 3 :~ N C~NN N H 3 H 3 C OH N O N N O CH 3 S- N N CH 3 CNNN SN N CH3N 3 CH K- NN OH 3 67 CI N N C Na o CH 3 O N N N 0 H 3 N I, N-F N NN & ~ I\ 5 CI N /\F N - F NO0 68 N F CN NN CN/ 0 -N 0,CH 3 1~0 H 3 C N N 'NN N 0 N 5 NN N 00 C' H 3 69 N /N o N N N ():N O N N N O N N 0 CH 3 /N~ N+a 0 CH 3 70 N N N N N 0 CH3 N, O N N N H 3 5 N N N OH 3 OH 3 C N : N OH 0 H 3 CH 3 0 71 N N CH 3 CI N NOH 3 O N cNa N OCH 3 N N N ccN O N N -N 0, H 3 0K N N 0 N 5 0c : N N / 0 / 72
8. A benzotriazole of the following structure as claimed in claim 7: -C N"" N OkN CH 3 N (:: N CH CCN N HH 0 0 H 3 N ():N/ N CH 3 10 CH 3 73 CI N N N O N 0: N O N H o/ K- C3 5
9. A process for preparing the compounds of the formula I as claimed in claims 1 to 8, which comprises a) acylating benzotriazole 2 with carbamoyl chlorides 3, or b) initially reacting benzotriazoles 2 with phosgene and then 10 reacting the resulting benzotriazolecarbonyl chlorides 5 with amines to give the compounds of the formula I, in which the substituents have the abovementioned meanings. R1 R2 N N + RR/L7 \ (N R4 R6 R4 N /R R3 N R5 R37 R4 R6# R4 R8 0 R7 R5 R6 2 3 74 R1 + C1 R1 N /On Re R2 N Ci R2 | N R7 R3 N R3 N R6 R4 R4 CI 2 5
10. Use of a benzotriazole of the formula I, R1 R2 N R3 N R4 N () R 7 0 R7 RS R6 5 in which the meanings are: R1 to Ra H; where one of these radicals R2 or R3 may represent: Br, C1, CH3, CN, NH 2 , NO 2 , CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH) phenyl, S-cyclohexyl, CO-OCH 3 ; 10 or two substituents of this series are: RI = Cl and R3 CF 3 or R2 = F and R3 Cl; n an integer from 0, 1 or 2; and 15 one of the substituents R6 or R7 may represent: R6 CH 3 ; R7 CH 3 , C 2 H 5 ; CH(CH 3 ) 2 , C(CH3)3, CF 3 , Br, Cl, benzyl or CO-OC 2 H 5 ; or 75 R6 and R7are both CH 3 ; or the ring may contain a double bond instead of R6 and R7 or R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring or else if n = 0 may 5 represent cyclohexanediyl; where in the case of the R6/R7 ring closure this substituent may be optionally substituted singly by NH 2 or NO 2 or singly or doubly by OCH 3 ; and R7 and R8 together cyclopentyl, diazirine or =CH 2 ; 10 in the manufacture of a medicament for inhibiting hormone sensitive lipase, HSL.
11. Use of a benzotriazole of the formula 1, R1 R2 N N R3 N R4 R7 R5 RS 15 in which the meanings are: R1 to R8 H; where one of these radicals R2 or R3 may represent: Br, Cl, CH 3 , CN, NH 2 , NO 2 , CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH) phenyl, S-cyclohexyl, CO-OCH 3 ; 20 or two substituents of this series are: R1 - Cl and R3 CF 3 or R2 = F and R3 = Cl; n an integer from 0, 1 or 2; and 25 one of the substituents R6 or R7 may represent: R6 CH 3 ; 76 R7 CH 3 , C 2 H 5 ; CH(CH 3 ) 2 , C(CH 3 )s, CF 3 , Br, Cl, benzyl or CO-OC 2 H 5 ; or R6 and R7are both CH 3 ; or the ring may contain a double bond instead of R6 and R7 or 5 R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring or else if n = 0 may represent cyclohexanedly; where in the case of the R6/R7 ring closure this substituent may be optionally substituted singly by NH 2 or NO 2 or singly or doubly by 10 OCH 3 ; and R7 and R8 together cyclopentyl, diazirine or =CH 2 ; in the manufacture of a medicament for the treatment of a disease selected from the group consisting of non-insulin dependent diabetes mellitus, diabetes syndrome and syndrome X. 15
12. A benzotriazole of the formula i, RI R2N N R3 N R4 N/ N R 7 0 R7 R5 RG as claimed in claim I and substantially as hereinbefore described with 20 reference to the Examples.
13. Use of a benzotriazole of the formula I as claimed in any one of claims 1 to 8 or 12 in the manufacture of a medicament for inhibiting hormone sensitive lipase, HSL. 25 77
14. Use of a benzotriazole of the formula I as claimed in any one of claims 1 to 8 or 12 in the manufacture of a medicament for the treatment of a disease selected from the group consisting of non-insulin dependent diabetes mellitus, diabetes syndrome and syndrome X. 5
15. A pharmaceutical composition comprising, as an active ingredient, a benzotriazole of the formula I as claimed in any one of claims I to 8 or 12. 10 16. A method of inhibiting hormone sensitive lipase, HSL, the method comprising administering to a patient in need thereof an effective amount of a benzotriazole of the formula I as claimed in any one of claims 1 to 8 or 12, or of the pharmaceutical composition as claimed in claim 15. 15 17. A method for the treatment of a disease selected from the group consisting of non-insulin-dependent diabetes mellitus, diabetic' syndrome, and syndrome X, the method comprising administering to a patient in need thereof an effective amount of a benzotriazole of the formula I as claimed in any one of claims 1 to 8 or 12, or of the pharmaceutical composition as 20 claimed in claim 15.
18. A process for preparing a benzotriazole of the formula I as claimed in claim 12, the process being substantially as hereinbefore described with reference to the Examples. 25
19. A method of inhibiting hormone sensitive lipase, HSL, the method comprising administering to a patient in need thereof an effective amount of a benzotriazole of the formula 1, 78 R1 R2 N N R4 R7 R5 R6 in which the meanings are: R1 to R8 H, where one of these radicals R2 or R3 may represent: 5 Br, Cl, CH 3 , CN, NH 2 , NO 2 , CF 3 , OCH 3 , phenoxy, benzoyl, CH(OH) phenyl, S-cyclohexyl, CO-OCH 3 ; or two substituents of this series are: R1 CI and R3 = CF 3 or 10 R2 =F and R3 CI; n an integer from 0, 1 or 2; and one of the substituents R6 or R7 may represent: R6 CH 3 ; R7 CH 3 , C2Hs; CH(CH 3 ) 2 , C(CH3)3, CF 3 , Br, Cl, benzyl or 15 CO-OC 2 H; or R6 and R7 are both CH 3 ; or the ring may contain a double bond instead of R6 and R7 or R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring or else if n 0 0 may 20 represent cyclohexanedlyl; where in the case of the R6/R7 ring closure this substituent may be optionally substituted singly by NH 2 or NO 2 or singly or doubly by OCH3; and R7 and R8 together cyclopentyl, diazirine or =CH 2 . 25 79
20. A method for the treatment of a disease selected from the group consisting of non-insulin-dependent diabetes mellitus, diabetes syndrome and syndrome X, the method comprising administering to a patient in need thereof an effective amount of a benzotriazole of the formula 1, 5 R1 R2 N R3 X N R4 N O R7 R5 R6 in which the meanings are: R1 to R8 H, where one of these radicals R2 or R3 may represent: 10 Br, Cl, CH 3 , CN, NH 2 , NO 2 , CF3, OCH, phenoxy, benzoyl, CH(OH) phenyl, S-cyclohexyl, CO-OCH3; or two substituents of this series are: R1 = CI and R3 = CF 3 or 15 R2 = F and R3= Cl; n an integer from 0, 1 or 2; and one of the substituents R6 or R7 may represent: R6 CH 3 ; R7 CH 3 , C 2 H 5 ; CH(CH 3 ) 2 , C(CH 3 ) 3 , CF 3 , Br, Cl, benzyl or 20 CO-OC 2 H; or R6 and R7 are both CH 3 ; or the ring may contain a double bond instead of R6 and R7 or R5 and R6 or R6 and R7 may together with the carbon atoms carrying them represent a benzo-fused ring or else if n = 0 may 25 represent cyclohexanediyl; where in the case of the R6/R7 ring closure this substituent may be optionally 80 substituted singly by NH 2 or NO 2 or singly or doubly by OCH 3 ; and R7 and R8 together cyclopentyl, diazirine or =CH 2 . 5 21. A method as claimed in claim 19 or claim 20 wherein the benzotriazole of the formula I is administered in the form of a pharmaceutical composition. 10 SANOFI-AVENTIS DEUTSCHLAND GMBH WATERMARK PATENT & TRADE MARK ATTORNEYS P25288AU00 15
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10247680A DE10247680B4 (en) | 2002-10-12 | 2002-10-12 | New bicyclic inhibitors of the hormone sensitive lipase |
DE10247680.2 | 2002-10-12 | ||
PCT/EP2003/010765 WO2004035550A1 (en) | 2002-10-12 | 2003-09-27 | Novel bicyclic inhibitors of hormone sensitive lipase |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2003275997A1 AU2003275997A1 (en) | 2004-05-04 |
AU2003275997B2 AU2003275997B2 (en) | 2010-03-25 |
AU2003275997B8 true AU2003275997B8 (en) | 2010-09-30 |
Family
ID=32038583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003275997A Ceased AU2003275997B8 (en) | 2002-10-12 | 2003-09-27 | Novel bicyclic inhibitors of hormone sensitive lipase |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP1554259B1 (en) |
JP (2) | JP4658607B2 (en) |
KR (1) | KR20050059254A (en) |
CN (1) | CN100366616C (en) |
AR (1) | AR041565A1 (en) |
AT (1) | ATE349433T1 (en) |
AU (1) | AU2003275997B8 (en) |
BR (1) | BR0315257A (en) |
CA (1) | CA2501734C (en) |
CR (1) | CR7717A (en) |
CY (1) | CY1106358T1 (en) |
DE (2) | DE10247680B4 (en) |
DK (1) | DK1554259T3 (en) |
EC (1) | ECSP055729A (en) |
ES (1) | ES2277152T3 (en) |
GT (1) | GT200300214A (en) |
HK (1) | HK1080473A1 (en) |
HN (1) | HN2003000316A (en) |
HR (1) | HRP20050325A2 (en) |
IL (1) | IL167907A (en) |
JO (1) | JO2497B1 (en) |
MA (1) | MA27404A1 (en) |
MX (1) | MXPA05003359A (en) |
MY (1) | MY138057A (en) |
NO (1) | NO20052291L (en) |
OA (1) | OA12941A (en) |
PA (1) | PA8585101A1 (en) |
PE (1) | PE20040776A1 (en) |
PL (1) | PL374605A1 (en) |
PT (1) | PT1554259E (en) |
RS (1) | RS51543B (en) |
RU (1) | RU2325385C2 (en) |
SV (1) | SV2004001633A (en) |
TN (1) | TNSN05105A1 (en) |
TW (1) | TWI313265B (en) |
UA (1) | UA79994C2 (en) |
UY (1) | UY28015A1 (en) |
WO (1) | WO2004035550A1 (en) |
ZA (1) | ZA200501757B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005002130A1 (en) | 2005-01-17 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | New substituted aminomethylene sulfonamides useful as hormone sensitive lipase inhibitors in medicaments for treatment and/or prevention of non-insulin dependent diabetes mellitus, diabetic syndrome or obesity |
DE102005026808A1 (en) | 2005-06-09 | 2006-12-14 | Sanofi-Aventis Deutschland Gmbh | Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases |
DE102005026762A1 (en) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases |
DE102005026809A1 (en) | 2005-06-09 | 2006-12-14 | Sanofi-Aventis Deutschland Gmbh | Benzothiazol-2-one derivatives as inhibitors of lipases and phospholipases |
DE102005048897A1 (en) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazole derivatives as inhibitors of lipases and phospholipases |
DE102005049953A1 (en) | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases |
DE102005049954A1 (en) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridine derivatives as inhibitors of lipases and phospholipases |
FR2915197B1 (en) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. |
FR2915198B1 (en) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | TRIAZOLOPYRIDINE CARBOXAMIDE AND TRIAZOLOPYRIDINE -CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
FR2915199B1 (en) * | 2007-04-18 | 2010-01-22 | Sanofi Aventis | TRIAZOLOPYRIDINE-CARBOXAMIDE AND TRIAZOLOPYRIMIDINE-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
CA2747784C (en) * | 2008-12-24 | 2018-07-31 | Bial - Portela & Ca, S.A. | Imidazole compounds for use as enzyme inhibitors |
US8329904B2 (en) | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
US8440710B2 (en) | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
US8097634B2 (en) | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
US8450350B2 (en) * | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
US8722721B2 (en) * | 2011-03-16 | 2014-05-13 | Hoffmann-La Roche Inc. | SEC-hydroxycyclohexyl derivatives |
US8703807B2 (en) * | 2011-03-17 | 2014-04-22 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
US8809384B2 (en) * | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
UA119247C2 (en) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
GB201321740D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
KR20210102887A (en) | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | Crystalline spirocyclic compound inhibitors of tryptophan hydroxylase 1 (TPH1) for treating diseases or disorders associated with peripheral serotonin |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4255510A (en) * | 1978-10-20 | 1981-03-10 | Eastman Kodak Company | Development restrainer precursors for photographic elements |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19942354A1 (en) * | 1999-09-04 | 2001-03-08 | Aventis Pharma Gmbh | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, their manufacture and use in medicinal products |
HUP0400048A3 (en) * | 2001-05-05 | 2008-10-28 | Smithkline Beecham Plc | N-aroyl cyclic amines and pharmaceutical compositions containing them |
BR0214967A (en) * | 2001-12-14 | 2005-05-10 | Novo Nordisk As | Compound, pharmaceutically acceptable salt, process for preparing a compound, pharmaceutical composition, use of a compound and method of treating a patient disorder |
-
2002
- 2002-10-12 DE DE10247680A patent/DE10247680B4/en not_active Expired - Fee Related
-
2003
- 2003-09-27 AU AU2003275997A patent/AU2003275997B8/en not_active Ceased
- 2003-09-27 BR BR0315257-0A patent/BR0315257A/en not_active IP Right Cessation
- 2003-09-27 PL PL03374605A patent/PL374605A1/en not_active Application Discontinuation
- 2003-09-27 UA UAA200504422A patent/UA79994C2/en unknown
- 2003-09-27 KR KR1020057006312A patent/KR20050059254A/en not_active Application Discontinuation
- 2003-09-27 JP JP2004544048A patent/JP4658607B2/en not_active Expired - Fee Related
- 2003-09-27 DE DE50306134T patent/DE50306134D1/en not_active Expired - Lifetime
- 2003-09-27 CA CA2501734A patent/CA2501734C/en not_active Expired - Fee Related
- 2003-09-27 EP EP03808700A patent/EP1554259B1/en not_active Expired - Lifetime
- 2003-09-27 PT PT03808700T patent/PT1554259E/en unknown
- 2003-09-27 OA OA1200500103A patent/OA12941A/en unknown
- 2003-09-27 MX MXPA05003359A patent/MXPA05003359A/en active IP Right Grant
- 2003-09-27 CN CNB038241420A patent/CN100366616C/en not_active Expired - Fee Related
- 2003-09-27 DK DK03808700T patent/DK1554259T3/en active
- 2003-09-27 ES ES03808700T patent/ES2277152T3/en not_active Expired - Lifetime
- 2003-09-27 RS YUP-2005/0207A patent/RS51543B/en unknown
- 2003-09-27 RU RU2005114394/04A patent/RU2325385C2/en not_active IP Right Cessation
- 2003-09-27 AT AT03808700T patent/ATE349433T1/en active
- 2003-09-27 WO PCT/EP2003/010765 patent/WO2004035550A1/en active IP Right Grant
- 2003-09-29 JO JO2003123A patent/JO2497B1/en active
- 2003-09-29 GT GT200300214A patent/GT200300214A/en unknown
- 2003-10-08 TW TW092127898A patent/TWI313265B/en active
- 2003-10-08 SV SV2003001633A patent/SV2004001633A/en not_active Application Discontinuation
- 2003-10-09 PA PA20038585101A patent/PA8585101A1/en unknown
- 2003-10-09 AR ARP030103676A patent/AR041565A1/en unknown
- 2003-10-09 HN HN2003000316A patent/HN2003000316A/en unknown
- 2003-10-09 PE PE2003001028A patent/PE20040776A1/en not_active Application Discontinuation
- 2003-10-10 UY UY28015A patent/UY28015A1/en unknown
- 2003-10-10 MY MYPI20033883A patent/MY138057A/en unknown
-
2005
- 2005-03-01 ZA ZA200501757A patent/ZA200501757B/en unknown
- 2005-03-07 CR CR7717A patent/CR7717A/en unknown
- 2005-04-07 IL IL167907A patent/IL167907A/en not_active IP Right Cessation
- 2005-04-11 HR HR20050325A patent/HRP20050325A2/en not_active Application Discontinuation
- 2005-04-11 MA MA28213A patent/MA27404A1/en unknown
- 2005-04-11 TN TNP2005000105A patent/TNSN05105A1/en unknown
- 2005-04-11 EC EC2005005729A patent/ECSP055729A/en unknown
- 2005-05-10 NO NO20052291A patent/NO20052291L/en not_active Application Discontinuation
-
2006
- 2006-01-10 HK HK06100358A patent/HK1080473A1/en not_active IP Right Cessation
-
2007
- 2007-03-06 CY CY20071100315T patent/CY1106358T1/en unknown
-
2010
- 2010-10-08 JP JP2010228107A patent/JP2011026342A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4255510A (en) * | 1978-10-20 | 1981-03-10 | Eastman Kodak Company | Development restrainer precursors for photographic elements |
US4256881A (en) * | 1978-10-20 | 1981-03-17 | Eastman Kodak Company | Blocked benzotriazole compounds as development restrainer precursors |
Non-Patent Citations (1)
Title |
---|
KATRITZKY, A. R. et al., J. Chem. Research (S), 1999, pages 230-231 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003275997B8 (en) | Novel bicyclic inhibitors of hormone sensitive lipase | |
DE102004005172A1 (en) | Indazole derivatives as inhibitors of the hormone sensitive lipase | |
AU2006303552A1 (en) | Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases | |
US7709513B2 (en) | Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors | |
AU2005209368A1 (en) | Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments | |
CA2610325A1 (en) | Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors | |
JP2008542411A (en) | Benzothiazol-2-one derivatives as lipase and phospholipase inhibitors | |
US7498341B2 (en) | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | |
US7262220B2 (en) | Urea- and urethane-substituted acylureas, process for their preparation and their use | |
US7470706B2 (en) | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | |
US7208504B2 (en) | Bicyclic inhibitors of hormone sensitive lipase | |
NZ539347A (en) | Novel bicyclic inhibitors of hormone sensitive lipase | |
KR20050105470A (en) | Substituted 3-(benzoylureido)-thiophene derivatives, method for the production and use thereof | |
JP4355290B2 (en) | Carboxyalkoxy substituted acyl-carboxyphenylurea derivatives, processes for their preparation and their use as pharmaceuticals | |
US20070088083A1 (en) | Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments | |
US7049341B2 (en) | N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH |
|
FGA | Letters patent sealed or granted (standard patent) | ||
TH | Corrigenda |
Free format text: IN VOL 24, NO 12, PAGE(S) 1374 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME SANOFI-AVENTIS DEUTSCHLAND GMBH, APPLICATION NO. 2003275997, UNDER INID (72) CORRECT THE COINVENTOR TO BARINGHAUS, KARL-HEINZ |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |